Xceleron appoints Dr Stuart Best
pharmafile | June 14, 2011 | Appointment | Manufacturing and Production, Research and Development | appointment, manufacturing and production, research and development
Dr Stuart Best has joined Xceleron as senior director operations, moving to the company from Merck in Scotland where he was head of bioanalysis.
Prior to Merck, Dr Best developed his reputation as an authority in the use of mass spectrometry in bioanalysis at Charles River (Inveresk).
Meanwhile, Xceleron has also added Dr David Roblin as a non-executive director.
Dr Roblin joins the York, UK-based drug development services company from Pfizer Global R&D, where he was most recently senior VP of R&D, research head and site director.
Xceleron chief executive Michael Butler said: “These two new additions to our team come at an exciting time for the Company. In the last two years Xceleron has more than doubled its ‘top 20’ pharmaceutical clients and is increasingly being asked to provide supporting data for critical events and regulatory submissions.
“David Roblin is a hugely valuable addition to our Board, he understands the nature of the challenge that large pharma companies face and will help us to continue to meet that need. Stuart Best is a seasoned pharma manager with a deep understanding of pharmaceutical clients’ operational needs and recognised expertise in the application of novel analytical technologies in drug regulatory development.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …






